TransMedics Group, Inc. (NASDAQ: TMDX) Stock Competitors & Peer Comparison
See TMDX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TMDX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TMDX | $88.58 | -1.18% | 3.1B | 44.96 | $1.97 | N/A |
| ABT | $111.25 | -0.02% | 192.5B | 21.35 | $5.21 | +2.23% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $339.21 | -0.55% | 129.8B | 25.29 | $13.39 | +1.02% |
| MDT | $91.27 | +0.76% | 116.8B | 16.50 | $5.53 | +3.11% |
| BSX | $51.83 | +0.27% | 77B | 16.72 | $3.10 | N/A |
| EW | $91.60 | -1.04% | 52.7B | 33.93 | $2.70 | N/A |
| DXCM | $89.75 | -1.16% | 34.5B | 39.26 | $2.33 | N/A |
| RMD | $224.46 | -1.01% | 32.6B | 20.84 | $10.77 | +1.07% |
| PHG | $27.29 | -0.33% | 26.7B | 15.59 | $1.75 | +3.62% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
TMDX vs ABT Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, ABT has a market cap of 192.5B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while ABT trades at $111.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas ABT's P/E ratio is 21.35. In terms of profitability, TMDX's ROE is +0.33%, compared to ABT's ROE of +0.11%. Regarding short-term risk, TMDX is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
TMDX vs BSX-PA Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, TMDX's ROE is +0.33%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, TMDX is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
TMDX vs SYK Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, SYK has a market cap of 129.8B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while SYK trades at $339.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas SYK's P/E ratio is 25.29. In terms of profitability, TMDX's ROE is +0.33%, compared to SYK's ROE of +0.16%. Regarding short-term risk, TMDX is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check SYK's competition here
Medtronic plc (NYSE: MDT)
TMDX vs MDT Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, MDT has a market cap of 116.8B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while MDT trades at $91.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas MDT's P/E ratio is 16.50. In terms of profitability, TMDX's ROE is +0.33%, compared to MDT's ROE of +0.10%. Regarding short-term risk, TMDX is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
TMDX vs BSX Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, BSX has a market cap of 77B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while BSX trades at $51.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas BSX's P/E ratio is 16.72. In terms of profitability, TMDX's ROE is +0.33%, compared to BSX's ROE of +0.15%. Regarding short-term risk, TMDX is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
TMDX vs EW Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, EW has a market cap of 52.7B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while EW trades at $91.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas EW's P/E ratio is 33.93. In terms of profitability, TMDX's ROE is +0.33%, compared to EW's ROE of +0.10%. Regarding short-term risk, TMDX is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
TMDX vs DXCM Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, DXCM has a market cap of 34.5B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while DXCM trades at $89.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas DXCM's P/E ratio is 39.26. In terms of profitability, TMDX's ROE is +0.33%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, TMDX is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
TMDX vs RMD Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, RMD has a market cap of 32.6B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while RMD trades at $224.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas RMD's P/E ratio is 20.84. In terms of profitability, TMDX's ROE is +0.33%, compared to RMD's ROE of +0.24%. Regarding short-term risk, TMDX is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
TMDX vs PHG Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, PHG has a market cap of 26.7B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while PHG trades at $27.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas PHG's P/E ratio is 15.59. In terms of profitability, TMDX's ROE is +0.33%, compared to PHG's ROE of +0.10%. Regarding short-term risk, TMDX is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
TMDX vs ZBH Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, ZBH has a market cap of 19.5B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while ZBH trades at $100.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas ZBH's P/E ratio is 11.87. In terms of profitability, TMDX's ROE is +0.33%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, TMDX is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
TMDX vs ABMD Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas ABMD's P/E ratio is 65.36. In terms of profitability, TMDX's ROE is +0.33%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, TMDX is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check ABMD's competition here
Align Technology, Inc. (NASDAQ: ALGN)
TMDX vs ALGN Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, ALGN has a market cap of 13B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while ALGN trades at $181.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas ALGN's P/E ratio is 16.53. In terms of profitability, TMDX's ROE is +0.33%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, TMDX is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check ALGN's competition here
Penumbra, Inc. (NYSE: PEN)
TMDX vs PEN Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while PEN trades at $327.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas PEN's P/E ratio is 85.38. In terms of profitability, TMDX's ROE is +0.33%, compared to PEN's ROE of +0.11%. Regarding short-term risk, TMDX is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
TMDX vs SWAV Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas SWAV's P/E ratio is 78.76. In terms of profitability, TMDX's ROE is +0.33%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, TMDX is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
TMDX vs SNN Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, SNN has a market cap of 12.5B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while SNN trades at $29.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas SNN's P/E ratio is 14.04. In terms of profitability, TMDX's ROE is +0.33%, compared to SNN's ROE of +0.12%. Regarding short-term risk, TMDX is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check SNN's competition here
Globus Medical, Inc. (NYSE: GMED)
TMDX vs GMED Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, GMED has a market cap of 11.6B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while GMED trades at $85.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas GMED's P/E ratio is 19.35. In terms of profitability, TMDX's ROE is +0.33%, compared to GMED's ROE of +0.12%. Regarding short-term risk, TMDX is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
TMDX vs GKOS Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, GKOS has a market cap of 10.9B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while GKOS trades at $184.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas GKOS's P/E ratio is -214.53. In terms of profitability, TMDX's ROE is +0.33%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, TMDX is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check GKOS's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
TMDX vs BIO-B Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, BIO-B has a market cap of 10.1B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while BIO-B trades at $368.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas BIO-B's P/E ratio is 109.45. In terms of profitability, TMDX's ROE is +0.33%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, TMDX is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check BIO-B's competition here
Insulet Corp. (NASDAQ: PODD)
TMDX vs PODD Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, PODD has a market cap of 9.9B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while PODD trades at $143.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas PODD's P/E ratio is 24.42. In terms of profitability, TMDX's ROE is +0.33%, compared to PODD's ROE of +0.27%. Regarding short-term risk, TMDX is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
TMDX vs BIO Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, BIO has a market cap of 9.6B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while BIO trades at $356.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas BIO's P/E ratio is 38.41. In terms of profitability, TMDX's ROE is +0.33%, compared to BIO's ROE of +0.03%. Regarding short-term risk, TMDX is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check BIO's competition here
Masimo Corporation (NASDAQ: MASI)
TMDX vs MASI Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas MASI's P/E ratio is 44.43. In terms of profitability, TMDX's ROE is +0.33%, compared to MASI's ROE of +0.09%. Regarding short-term risk, TMDX is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
TMDX vs BRKR Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, BRKR has a market cap of 8.8B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while BRKR trades at $57.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas BRKR's P/E ratio is 28.99. In terms of profitability, TMDX's ROE is +0.33%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, TMDX is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BRKR's competition here
Inari Medical, Inc. (NASDAQ: NARI)
TMDX vs NARI Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas NARI's P/E ratio is -59.24. In terms of profitability, TMDX's ROE is +0.33%, compared to NARI's ROE of -0.00%. Regarding short-term risk, TMDX is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
TMDX vs LIVN Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, LIVN has a market cap of 4.5B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while LIVN trades at $82.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas LIVN's P/E ratio is 19.53. In terms of profitability, TMDX's ROE is +0.33%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, TMDX is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
TMDX vs ITGR Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while ITGR trades at $125.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas ITGR's P/E ratio is 19.73. In terms of profitability, TMDX's ROE is +0.33%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, TMDX is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
TMDX vs IRTC Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, IRTC has a market cap of 4.2B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while IRTC trades at $126.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas IRTC's P/E ratio is -197.56. In terms of profitability, TMDX's ROE is +0.33%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, TMDX is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check IRTC's competition here
Haemonetics Corporation (NYSE: HAE)
TMDX vs HAE Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, HAE has a market cap of 4.1B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while HAE trades at $90.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas HAE's P/E ratio is 18.14. In terms of profitability, TMDX's ROE is +0.33%, compared to HAE's ROE of +0.11%. Regarding short-term risk, TMDX is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check HAE's competition here
Axonics, Inc. (NASDAQ: AXNX)
TMDX vs AXNX Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas AXNX's P/E ratio is -709.80. In terms of profitability, TMDX's ROE is +0.33%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, TMDX is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check AXNX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
TMDX vs AXGN Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, AXGN has a market cap of 2.6B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while AXGN trades at $48.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas AXGN's P/E ratio is 128.24. In terms of profitability, TMDX's ROE is +0.33%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, TMDX is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
TMDX vs UFPT Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, UFPT has a market cap of 2.5B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while UFPT trades at $321.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas UFPT's P/E ratio is 32.87. In terms of profitability, TMDX's ROE is +0.33%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, TMDX is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check UFPT's competition here
Butterfly Network, Inc. (NYSE: BFLY)
TMDX vs BFLY Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while BFLY trades at $8.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas BFLY's P/E ratio is -36.79. In terms of profitability, TMDX's ROE is +0.33%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, TMDX is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BFLY's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
TMDX vs ESTA Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, ESTA has a market cap of 2.3B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while ESTA trades at $79.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas ESTA's P/E ratio is -63.07. In terms of profitability, TMDX's ROE is +0.33%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, TMDX is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
TMDX vs NUVA Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas NUVA's P/E ratio is 75.00. In terms of profitability, TMDX's ROE is +0.33%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, TMDX is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
TMDX vs NVCR Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while NVCR trades at $16.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas NVCR's P/E ratio is -11.08. In terms of profitability, TMDX's ROE is +0.33%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, TMDX is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
TMDX vs INSP Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, INSP has a market cap of 1.6B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while INSP trades at $57.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas INSP's P/E ratio is 25.13. In terms of profitability, TMDX's ROE is +0.33%, compared to INSP's ROE of +0.18%. Regarding short-term risk, TMDX is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check INSP's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
TMDX vs TNDM Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, TNDM has a market cap of 1.6B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while TNDM trades at $22.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas TNDM's P/E ratio is -20.65. In terms of profitability, TMDX's ROE is +0.33%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, TMDX is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check TNDM's competition here
CONMED Corporation (NYSE: CNMD)
TMDX vs CNMD Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while CNMD trades at $50.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas CNMD's P/E ratio is 11.09. In terms of profitability, TMDX's ROE is +0.33%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, TMDX is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
TMDX vs ATEC Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while ATEC trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas ATEC's P/E ratio is -163.17. In terms of profitability, TMDX's ROE is +0.33%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, TMDX is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check ATEC's competition here
Enovis Corporation (NYSE: ENOV)
TMDX vs ENOV Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while ENOV trades at $26.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas ENOV's P/E ratio is 7.47. In terms of profitability, TMDX's ROE is +0.33%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, TMDX is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check ENOV's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
TMDX vs IART Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while IART trades at $18.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas IART's P/E ratio is 7.77. In terms of profitability, TMDX's ROE is +0.33%, compared to IART's ROE of -0.01%. Regarding short-term risk, TMDX is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check IART's competition here
Artivion, Inc. (NYSE: AORT)
TMDX vs AORT Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while AORT trades at $29.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas AORT's P/E ratio is 48.60. In terms of profitability, TMDX's ROE is +0.33%, compared to AORT's ROE of -0.01%. Regarding short-term risk, TMDX is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check AORT's competition here
Heska Corporation (NASDAQ: HSKA)
TMDX vs HSKA Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas HSKA's P/E ratio is -62.49. In terms of profitability, TMDX's ROE is +0.33%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, TMDX is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check HSKA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
TMDX vs PRCT Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while PRCT trades at $21.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas PRCT's P/E ratio is -11.16. In terms of profitability, TMDX's ROE is +0.33%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, TMDX is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
TMDX vs AVNS Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas AVNS's P/E ratio is 27.77. In terms of profitability, TMDX's ROE is +0.33%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, TMDX is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check AVNS's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
TMDX vs LMRI Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, LMRI has a market cap of 1.2B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while LMRI trades at $12.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas LMRI's P/E ratio is -23.39. In terms of profitability, TMDX's ROE is +0.33%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, TMDX is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
TMDX vs SILK Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas SILK's P/E ratio is -18.96. In terms of profitability, TMDX's ROE is +0.33%, compared to SILK's ROE of -0.35%. Regarding short-term risk, TMDX is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
TMDX vs IRMD Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while IRMD trades at $86.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas IRMD's P/E ratio is 43.69. In terms of profitability, TMDX's ROE is +0.33%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, TMDX is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
TMDX vs FNA Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas FNA's P/E ratio is -19.83. In terms of profitability, TMDX's ROE is +0.33%, compared to FNA's ROE of -0.35%. Regarding short-term risk, TMDX is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
TMDX vs BVS Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, BVS has a market cap of 966.1M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while BVS trades at $14.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas BVS's P/E ratio is 18.76. In terms of profitability, TMDX's ROE is +0.33%, compared to BVS's ROE of +0.28%. Regarding short-term risk, TMDX is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BVS's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
TMDX vs AVR Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, AVR has a market cap of 914M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while AVR trades at $9.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas AVR's P/E ratio is -4.22. In terms of profitability, TMDX's ROE is +0.33%, compared to AVR's ROE of -0.78%. Regarding short-term risk, TMDX is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check AVR's competition here
CeriBell, Inc. (NASDAQ: CBLL)
TMDX vs CBLL Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, CBLL has a market cap of 885.2M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while CBLL trades at $23.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas CBLL's P/E ratio is -14.31. In terms of profitability, TMDX's ROE is +0.33%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, TMDX is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check CBLL's competition here
InMode Ltd. (NASDAQ: INMD)
TMDX vs INMD Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, INMD has a market cap of 870.8M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while INMD trades at $15.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas INMD's P/E ratio is 10.52. In terms of profitability, TMDX's ROE is +0.33%, compared to INMD's ROE of +0.12%. Regarding short-term risk, TMDX is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check INMD's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
TMDX vs CSII Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas CSII's P/E ratio is -20.83. In terms of profitability, TMDX's ROE is +0.33%, compared to CSII's ROE of -0.14%. Regarding short-term risk, TMDX is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
TMDX vs SIBN Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, SIBN has a market cap of 839.5M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while SIBN trades at $18.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas SIBN's P/E ratio is -55.68. In terms of profitability, TMDX's ROE is +0.33%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, TMDX is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check SIBN's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
TMDX vs AHCO Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, AHCO has a market cap of 790.5M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while AHCO trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas AHCO's P/E ratio is 11.86. In terms of profitability, TMDX's ROE is +0.33%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, TMDX is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check AHCO's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
TMDX vs BBNX Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, BBNX has a market cap of 790.5M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while BBNX trades at $17.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas BBNX's P/E ratio is -11.64. In terms of profitability, TMDX's ROE is +0.33%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, TMDX is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BBNX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
TMDX vs SSII Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, SSII has a market cap of 778.5M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while SSII trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas SSII's P/E ratio is -75.87. In terms of profitability, TMDX's ROE is +0.33%, compared to SSII's ROE of -0.27%. Regarding short-term risk, TMDX is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check SSII's competition here
Varex Imaging Corporation (NASDAQ: VREX)
TMDX vs VREX Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, VREX has a market cap of 778.4M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while VREX trades at $18.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas VREX's P/E ratio is 19.46. In terms of profitability, TMDX's ROE is +0.33%, compared to VREX's ROE of +0.05%. Regarding short-term risk, TMDX is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check VREX's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
TMDX vs BWAY Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, BWAY has a market cap of 640.1M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while BWAY trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas BWAY's P/E ratio is 41.46. In terms of profitability, TMDX's ROE is +0.33%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, TMDX is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BWAY's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
TMDX vs KIDS Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, KIDS has a market cap of 637M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while KIDS trades at $24.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas KIDS's P/E ratio is -21.02. In terms of profitability, TMDX's ROE is +0.33%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, TMDX is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check KIDS's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
TMDX vs CTKB Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, CTKB has a market cap of 631.5M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while CTKB trades at $4.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas CTKB's P/E ratio is -25.91. In terms of profitability, TMDX's ROE is +0.33%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, TMDX is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check CTKB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
TMDX vs SRDX Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas SRDX's P/E ratio is -34.66. In terms of profitability, TMDX's ROE is +0.33%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, TMDX is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check SRDX's competition here
Cerus Corporation (NASDAQ: CERS)
TMDX vs CERS Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, CERS has a market cap of 600.5M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while CERS trades at $2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas CERS's P/E ratio is -59.48. In terms of profitability, TMDX's ROE is +0.33%, compared to CERS's ROE of -0.10%. Regarding short-term risk, TMDX is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check CERS's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
TMDX vs DCTH Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, DCTH has a market cap of 599.3M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while DCTH trades at $16.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas DCTH's P/E ratio is 1736.00. In terms of profitability, TMDX's ROE is +0.33%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, TMDX is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check DCTH's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
TMDX vs APEN Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas APEN's P/E ratio is -9.43. In terms of profitability, TMDX's ROE is +0.33%, compared to APEN's ROE of -0.85%. Regarding short-term risk, TMDX is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check APEN's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
TMDX vs TCMD Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, TCMD has a market cap of 545.9M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while TCMD trades at $24.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas TCMD's P/E ratio is 27.50. In terms of profitability, TMDX's ROE is +0.33%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, TMDX is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check TCMD's competition here
ZimVie Inc. (NASDAQ: ZIMV)
TMDX vs ZIMV Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, TMDX's ROE is +0.33%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, TMDX is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check ZIMV's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
TMDX vs NPCE Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, NPCE has a market cap of 503.6M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while NPCE trades at $14.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas NPCE's P/E ratio is -22.72. In terms of profitability, TMDX's ROE is +0.33%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, TMDX is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
TMDX vs CLPT Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, CLPT has a market cap of 460M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while CLPT trades at $15.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas CLPT's P/E ratio is -13.00. In terms of profitability, TMDX's ROE is +0.33%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, TMDX is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check CLPT's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
TMDX vs SGHT Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, SGHT has a market cap of 442.9M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while SGHT trades at $8.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas SGHT's P/E ratio is -14.54. In terms of profitability, TMDX's ROE is +0.33%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, TMDX is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check SGHT's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
TMDX vs OFIX Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, OFIX has a market cap of 418M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while OFIX trades at $10.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas OFIX's P/E ratio is -13.51. In terms of profitability, TMDX's ROE is +0.33%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, TMDX is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check OFIX's competition here
Carlsmed, Inc. (NASDAQ: CARL)
TMDX vs CARL Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, CARL has a market cap of 389.3M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while CARL trades at $14.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas CARL's P/E ratio is -10.01. In terms of profitability, TMDX's ROE is +0.33%, compared to CARL's ROE of -0.38%. Regarding short-term risk, TMDX is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check CARL's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
TMDX vs CATX Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, CATX has a market cap of 366.1M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while CATX trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas CATX's P/E ratio is -2.28. In terms of profitability, TMDX's ROE is +0.33%, compared to CATX's ROE of -0.42%. Regarding short-term risk, TMDX is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check CATX's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
TMDX vs PACB Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, PACB has a market cap of 357.2M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while PACB trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas PACB's P/E ratio is -2.80. In terms of profitability, TMDX's ROE is +0.33%, compared to PACB's ROE of -49.62%. Regarding short-term risk, TMDX is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check PACB's competition here
Picard Medical, Inc. (AMEX: PMI)
TMDX vs PMI Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, PMI has a market cap of 353.3M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while PMI trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas PMI's P/E ratio is -2.87. In terms of profitability, TMDX's ROE is +0.33%, compared to PMI's ROE of +4.99%. Regarding short-term risk, TMDX is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check PMI's competition here
Electromed, Inc. (AMEX: ELMD)
TMDX vs ELMD Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, ELMD has a market cap of 342.6M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while ELMD trades at $41.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas ELMD's P/E ratio is 35.37. In terms of profitability, TMDX's ROE is +0.33%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, TMDX is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check ELMD's competition here
CapsoVision, Inc. (NASDAQ: CV)
TMDX vs CV Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, CV has a market cap of 339.3M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while CV trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas CV's P/E ratio is -2.72. In terms of profitability, TMDX's ROE is +0.33%, compared to CV's ROE of -1.78%. Regarding short-term risk, TMDX is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check CV's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
TMDX vs SENS Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, SENS has a market cap of 326.4M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while SENS trades at $7.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas SENS's P/E ratio is -3.90. In terms of profitability, TMDX's ROE is +0.33%, compared to SENS's ROE of -1.66%. Regarding short-term risk, TMDX is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check SENS's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
TMDX vs TLSI Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, TLSI has a market cap of 324.5M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while TLSI trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas TLSI's P/E ratio is -3.14. In terms of profitability, TMDX's ROE is +0.33%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, TMDX is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check TLSI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
TMDX vs SMLR Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas SMLR's P/E ratio is 3.92. In terms of profitability, TMDX's ROE is +0.33%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, TMDX is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
TMDX vs TMCI Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, TMCI has a market cap of 310.7M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while TMCI trades at $4.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas TMCI's P/E ratio is -5.10. In terms of profitability, TMDX's ROE is +0.33%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, TMDX is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check TMCI's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
TMDX vs ANIK Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, ANIK has a market cap of 287.7M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while ANIK trades at $21.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas ANIK's P/E ratio is 43.88. In terms of profitability, TMDX's ROE is +0.33%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, TMDX is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check ANIK's competition here
RxSight, Inc. (NASDAQ: RXST)
TMDX vs RXST Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, RXST has a market cap of 285.2M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while RXST trades at $6.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas RXST's P/E ratio is -7.41. In terms of profitability, TMDX's ROE is +0.33%, compared to RXST's ROE of -0.17%. Regarding short-term risk, TMDX is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check RXST's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
TMDX vs MGRM Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas MGRM's P/E ratio is -12.00. In terms of profitability, TMDX's ROE is +0.33%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, TMDX is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check MGRM's competition here
Profound Medical Corp. (NASDAQ: PROF)
TMDX vs PROF Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, PROF has a market cap of 240.9M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while PROF trades at $6.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas PROF's P/E ratio is -5.35. In terms of profitability, TMDX's ROE is +0.33%, compared to PROF's ROE of -0.56%. Regarding short-term risk, TMDX is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check PROF's competition here
Neuronetics, Inc. (NASDAQ: STIM)
TMDX vs STIM Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, STIM has a market cap of 229.6M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while STIM trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas STIM's P/E ratio is -6.11. In terms of profitability, TMDX's ROE is +0.33%, compared to STIM's ROE of -1.51%. Regarding short-term risk, TMDX is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check STIM's competition here
Nevro Corp. (NYSE: NVRO)
TMDX vs NVRO Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas NVRO's P/E ratio is -1.91. In terms of profitability, TMDX's ROE is +0.33%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, TMDX is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check NVRO's competition here
Avita Medical Inc. (NASDAQ: RCEL)
TMDX vs RCEL Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, RCEL has a market cap of 195M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while RCEL trades at $7.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas RCEL's P/E ratio is -5.00. In terms of profitability, TMDX's ROE is +0.33%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, TMDX is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check RCEL's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
TMDX vs BSGM Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas BSGM's P/E ratio is -5.81. In terms of profitability, TMDX's ROE is +0.33%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, TMDX is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
TMDX vs LUCD Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, LUCD has a market cap of 184.6M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while LUCD trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas LUCD's P/E ratio is -2.62. In terms of profitability, TMDX's ROE is +0.33%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, TMDX is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
TMDX vs MDGS Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas MDGS's P/E ratio is -0.27. In terms of profitability, TMDX's ROE is +0.33%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, TMDX is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check MDGS's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
TMDX vs FOCL Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, FOCL has a market cap of 178.4M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while FOCL trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas FOCL's P/E ratio is -5.81. In terms of profitability, TMDX's ROE is +0.33%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, TMDX is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check FOCL's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
TMDX vs QIPT Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas QIPT's P/E ratio is -15.87. In terms of profitability, TMDX's ROE is +0.33%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, TMDX is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check QIPT's competition here
Inogen, Inc. (NASDAQ: INGN)
TMDX vs INGN Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, INGN has a market cap of 155.7M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while INGN trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas INGN's P/E ratio is -6.32. In terms of profitability, TMDX's ROE is +0.33%, compared to INGN's ROE of -0.13%. Regarding short-term risk, TMDX is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
TMDX vs QTRX Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, QTRX has a market cap of 122M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while QTRX trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas QTRX's P/E ratio is -1.62. In terms of profitability, TMDX's ROE is +0.33%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, TMDX is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check QTRX's competition here
Owlet, Inc. (NYSE: OWLT)
TMDX vs OWLT Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, OWLT has a market cap of 120.9M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while OWLT trades at $6.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas OWLT's P/E ratio is -47.71. In terms of profitability, TMDX's ROE is +0.33%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, TMDX is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check OWLT's competition here
iCAD, Inc. (NASDAQ: ICAD)
TMDX vs ICAD Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas ICAD's P/E ratio is -20.37. In terms of profitability, TMDX's ROE is +0.33%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, TMDX is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check ICAD's competition here
Pulmonx Corporation (NASDAQ: LUNG)
TMDX vs LUNG Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, LUNG has a market cap of 102.2M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while LUNG trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas LUNG's P/E ratio is -1.86. In terms of profitability, TMDX's ROE is +0.33%, compared to LUNG's ROE of -0.97%. Regarding short-term risk, TMDX is less volatile compared to LUNG. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check LUNG's competition here
Solana Company (NASDAQ: HSDT)
TMDX vs HSDT Comparison August 2026
TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMDX stands at 3.1B. In comparison, HSDT has a market cap of 101.6M. Regarding current trading prices, TMDX is priced at $88.58 on the NASDAQ, while HSDT trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMDX currently has a P/E ratio of 44.96, whereas HSDT's P/E ratio is -0.02. In terms of profitability, TMDX's ROE is +0.33%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, TMDX is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check HSDT's competition here